These innovative agents represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://anniehcdb786623.blog4youth.com/39678688/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide